Fig. 8
Survival curves for the different treatments assayed in B16OVA melanoma-bearing mice. B16OVA tumor bearing mice intravenously administered with three cycles (cycle/every 72 h) of different treatments: saline, free Dox, Conventional Dox liposomes (LPD), LPD co-administered with 28 µg of free α-PD-L1 or Targeted Dox liposome or immunoliposomes (LPF). Dox was intravenously administered at 3 mg/kg and tumor progression was measured twice per week. Immunoliposomes increased significantly the survival rate in comparison with the other treatments (***p < 0.001)